Last edition
News about
Breakthru Medicine Raises USD 60 Million Series A to Advance Cancer Drugs
Founded by biotech veterans Steve Potts, Mark Mulvihill and Brian Barnett, Breakthru Medicine has raised USD 60 million in Series A funding to advance its stealth oncology pipeline, including molecular glues, small molecules and novel ADC payloads.
Union Budget Boosts Pharma with Biopharma Shakti with Outlay of INR 10,000 Crore
Union Finance Minister Nirmala Sitharaman unveiled multiple initiatives for pharma and life sciences in budget 2026–27, including Biopharma Shakti, NIPER expansion, CDSCO strengthening and new investments, to position India as a global biopharma hub.
FDA Approves Tenpoint Therapeutics' Yuvezzi, First Dual-Action Eye Drop for Presbyopia
The US FDA has approved Yuvezzi (carbachol and brimonidine tartrate), the first dual-agent eye drop for presbyopia, offering significant near-vision improvement with favourable tolerability.
China's NMPA approves Almirall's Seysara for Moderate-to-Severe Acne Treatment
China’s NMPA has approved Almirall’s Seysara (sarecycline hydrochloride), the first oral antibiotic developed specifically for acne, expanding access to innovative dermatology treatment in partnership with Sinomune.
IQVIA and Boehringer Ingelheim Partner on Global Commercial Data Transformation
The long-term strategic collaboration aims to modernise Boehringer Ingelheim’s global commercial data foundation, enabling scalable, advanced analytics across therapeutic areas and regions using IQVIA’s industry-leading data model.
AstraZeneca Boosts Weight Management Portfolio via CSPC Collaboration
Under this agreement, Astrazeneca and CSPC Pharmaceuticals will initially progress four programmes, which utilise CSPC's advanced Artificial Intelligence (AI)-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.
Frontage Labs Expands Early-Phase Clinical Capabilities for Global Drug Development
Frontage's US operations are anchored by a modern 160?bed, 36,000?sq?ft phase-I clinical unit in Secaucus, New Jersey, designed to conduct large?scale phase-I and bioequivalence (BE) studies as well as radiolabeled human AME research.
Mabtech and Sai Life Sciences Partner to Advance Immunology Research
Under this collaboration, Mabtech and Sai will jointly deliver advanced immunology assay services — including high-sensitivity multiplex cytokine and phenotyping workflows — powered by the EYRA platform installed at Sai’s Boston discovery site.
Lilly Announces USD 3.5 Billion Injectable Drug and Device Manufacturing Facility in Pennsylvania
Eli Lilly and Company has announced plans to invest USD 3.5 billion to build a new injectable drug and device manufacturing facility in the Lehigh Valley region of Pennsylvania, marking one of the largest life sciences investments in the state’s history.
USA Biomanufacturing Investment Surges Nearly 20 Percent, Report Finds
Investment in biomanufacturing across the USA has recorded a sharp rise, with pledged capital increasing by nearly 20 percent since 2024, according to a recent industry report. The surge positions biomanufacturing as one of the fastest-growing segments within the country’s advanced manufacturing landscape.
<br />
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy